1. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL, McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5;68(6):895-902.
2. US CDC. Influenza Antiviral Medications: Summary for Clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#:~:text=The%20recommended%20treatment%20course%20for,oral%20baloxavir%20for%201%20day.
3. CDC. What You Should Know About Flu Antiviral Drugs. https://www.cdc.gov/flu/treatment/whatyoushould.htm
4. CDC. Influenza Antiviral Drug Resistance. https://www.cdc.gov/flu/treatment/antiviralresistance.htm
5. Baker JB, Block SL, Cagas SE, Macutkiewicz LB, Collins C, Sadeghi M, Sarkar S, Williams S. Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study. Pediatr Infect Dis J. 2023 Nov 1;42(11):983-989.
5. Mayo clinic. Baloxavir Marboxil
(Oral Route):https://www.mayoclinic.org/drugs-supplements/baloxavir-marboxil-oral-route/proper-use/drg-20452251?p=1
6. European Medicines Agency. Xofluza, INN-baloxavir marboxil. https://www.ema.europa.eu/en/documents/product-information/xofluza-epar-product-information_en.pdf